Attention will come with this 1st commercial TCR i
Post# of 1
Posted On: 09/29/2016 4:02:37 AM
Attention will come with this 1st commercial TCR immunotherapy deal of German Medigene AG with Bluebird Bio for 4 TCR targets with an upfront of $15m, up to $1b milestones of paid R&D and further gains on future net-sales
bluebirds press release
http://investor.bluebirdbio.com/phoenix.zhtml...ID=2206710
See this short video to understand Medigene AG TCR T-cell approach:
https://vimeo.com/123005836
bluebirds press release
http://investor.bluebirdbio.com/phoenix.zhtml...ID=2206710
See this short video to understand Medigene AG TCR T-cell approach:
https://vimeo.com/123005836
(1)
(0)MediGene AG (MDGEF) Stock Research Links
Scroll down for more posts ▼